227 related articles for article (PubMed ID: 26208485)
1. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.
Chien AJ; Duralde E; Hwang R; Tsung K; Kao CN; Rugo HS; Melisko ME; Esserman LJ; Munster PN; Cedars M; Kerlikowske K; McCulloch CE; Rosen MP
Breast Cancer Res Treat; 2015 Aug; 153(1):173-81. PubMed ID: 26208485
[TBL] [Abstract][Full Text] [Related]
2. Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels.
Meng K; Tian W; Zhou M; Chen H; Deng Y
World J Surg Oncol; 2013 May; 11():101. PubMed ID: 23688389
[TBL] [Abstract][Full Text] [Related]
3. Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study.
Yamazaki R; Inokuchi M; Ishikawa S; Ayabe T; Jinno H; Iizuka T; Ono M; Myojo S; Uchida S; Matsuzaki T; Tangoku A; Kita M; Sugie T; Fujiwara H
BMC Cancer; 2020 Jan; 20(1):67. PubMed ID: 31996163
[TBL] [Abstract][Full Text] [Related]
4. Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
Kim HJ; Noh WC; Nam SJ; Park BW; Lee ES; Im SA; Jung YS; Yoon JH; Kang SS; Park KH; Lee SJ; Jeong J; Lee MH; Cho SH; Kim SY; Kim HA; Han SH; Han W; Hur MH; Kim S; Ahn SH
Eur J Cancer; 2021 Jul; 151():190-200. PubMed ID: 34010788
[TBL] [Abstract][Full Text] [Related]
5. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
6. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
[TBL] [Abstract][Full Text] [Related]
7. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
[TBL] [Abstract][Full Text] [Related]
8. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.
Guerrero A; Gavilá J; Folkerd E; Ortiz B; Martínez F; García A; Climent MA; Guillem V; Ruíz A
Ann Oncol; 2013 Mar; 24(3):674-9. PubMed ID: 23108951
[TBL] [Abstract][Full Text] [Related]
9. Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer.
Xue C; Peng R; Cao Y; Wang S; Shi Y; An X; Xu F; Yuan Z
PLoS One; 2016; 11(2):e0148849. PubMed ID: 26866810
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
He W; Fang F; Varnum C; Eriksson M; Hall P; Czene K
J Clin Oncol; 2015 Jul; 33(20):2262-9. PubMed ID: 26033800
[TBL] [Abstract][Full Text] [Related]
11. Feature of amenorrhea in postoperative tamoxifen users with breast cancer.
Kim H; Han W; Ku SY; Suh CS; Kim SH; Choi YM
J Gynecol Oncol; 2017 Mar; 28(2):e10. PubMed ID: 27894163
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen and ovarian function.
Berliere M; Duhoux FP; Dalenc F; Baurain JF; Dellevigne L; Galant C; Van Maanen A; Piette P; Machiels JP
PLoS One; 2013; 8(6):e66616. PubMed ID: 23840510
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
14. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
[TBL] [Abstract][Full Text] [Related]
15. Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival.
Collichio F; Pandya K
Oncology (Williston Park); 1994 Dec; 8(12):45-52. PubMed ID: 7888312
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
Vehmanen L; Elomaa I; Blomqvist C; Saarto T
J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
[TBL] [Abstract][Full Text] [Related]
17. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
Jordan VC; Fritz NF; Tormey DC
Cancer Res; 1987 Jan; 47(2):624-30. PubMed ID: 3098415
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cysts in tamoxifen-treated women with breast cancer.
Inal MM; Incebiyik A; Sanci M; Yildirim Y; Polat M; Pilanci B; Nayki C; Camuzcuoğlu H
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):104-6. PubMed ID: 15866095
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cyst formation in patients using tamoxifen for breast cancer.
Metindir J; Aslan S; Bilir G
Jpn J Clin Oncol; 2005 Oct; 35(10):607-11. PubMed ID: 16254040
[TBL] [Abstract][Full Text] [Related]
20. Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer.
Torino F; Barnabei A; De Vecchis L; Appetecchia M; Strigari L; Corsello SM
Endocr Relat Cancer; 2012 Apr; 19(2):R21-33. PubMed ID: 22241718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
